Cite
Anastassova N, Aluani D, Kostadinov A, et al. Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation. Neural Regen Res. 2021;16(11):2299-2309doi: 10.4103/1673-5374.309843.
Anastassova, N., Aluani, D., Kostadinov, A., Rangelov, M., Todorova, N., Hristova-Avakumova, N., Argirova, M., Lumov, N., Kondeva-Burdina, M., Tzankova, V., & Yancheva, D. (2021). Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation. Neural regeneration research, 16(11), 2299-2309. https://doi.org/10.4103/1673-5374.309843
Anastassova, Neda, et al. "Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation." Neural regeneration research vol. 16,11 (2021): 2299-2309. doi: https://doi.org/10.4103/1673-5374.309843
Anastassova N, Aluani D, Kostadinov A, Rangelov M, Todorova N, Hristova-Avakumova N, Argirova M, Lumov N, Kondeva-Burdina M, Tzankova V, Yancheva D. Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation. Neural Regen Res. 2021 Nov;16(11):2299-2309. doi: 10.4103/1673-5374.309843. PMID: 33818516; PMCID: PMC8354139.
Copy
Download .nbib
